Clinical trial · Interventional
[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
NCT04693169CI-TRIAL-00073310unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the radioactive uptake of \[Al 18 F\]PSMA137 in PCa patients, and evaluate the ability of \[Al 18 F\]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an approach for screening patients high expression of PSMA, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 11C-Choline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [Al18F]PSMA137 PET/CT imaging
- description
- All study participants will be allocated to this arm (single-arm study).Study participants will undergo \[Al18F\]PSMA137 PET/CT scans.
- interventionNames
- Drug: 11C-Choline
Primary outcomes (1)
- measure
- SUV（standardized uptake value）
- timeFrame
- 2 years
- description
- SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions。 The uptake of the tracer （\[Al18F\]PSMA137） in the primary and metastatic tumor lesions by measuring SUV on PET/CT
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Men over 18 years of age need to undergo \[Al18F\]PSMA137 PET/CT examination for suspected prostate cancer. * The patients can fully understand and voluntarily participate in this experiment, and sign the informed consent. Exclusion Criteria: * Significant hepatic or renal dysfunction; * Patients with malignant tumors other than prostate cancer within 2 years; * Ready to pregnant; * The patient can not tolerate all clinical tests.
References
Publications (0)
Data not yet available
No reference posted for this study.